Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in high-risk adults with type 2 diabetes.Approval of oral semaglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback